pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-5-610-617pulmo-770Research ArticleОБЗОРЫREVIEWПАТОГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ ФОРМИРОВАНИЯ СЕРДЕЧНО-СОСУДИСТОГО КОНТИНУУМА ПРИ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХPATHOGENIC PARTICULARITIES OF CARDIOVASCULAR CONTINUUM IN CHRONIC OBSTRUCTIVE PULMONARY DISEASEВатутинН. Т.VatutinN. T.

д. м. н., профессор, зав. кафедрой госпитальной терапии

MD, Professor, Head of Department of Hospital Internal Medicine

kafedra_vatutin@mail.ruСмирноваА. С.SmirnovaA. S.

к. м. н., ассистент кафедры госпитальной терапии

PhD, Assistant Lecturer at Department of Hospital Internal Medicine

a.smyrnova@mail.ruБортД. В.BortD. V.

врач-интерн

Junior Physician at V.K.Gusak’ State Institute of Urgent and Reconstructive Surgery

bortdima2@mail.ruТарадинГ. Г.TaradinG. G.

к. м. н., доцент кафедры госпитальной терапии

PhD, Associate Professor at Department of Hospital Internal Medicine

taradin@inbox.ruДонецкий национальный медицинский университет имени М.Горького: 83005, Украина, Донецк, пр. Ильича, 14; ГУ «Институт неотложной и восстановительной хирургии имени В.К.Гусака НАМН Украины»: 83000, Украина, Донецк, Ленинский проспект, 47УкраинаM.Gor'kiy Donetsk National Medical University: 14; Il'icha av., Donetsk, 83005, Ukraine; V.K.Gusak State Institute of Urgent and Reconstructive Surgery, National Medical Science Academy of Ukraine: 47, Leninskiy av., Donetsk, 83000, UkraineUkraineДонецкий национальный медицинский университет имени М.Горького: 83005, Украина, Донецк, пр. Ильича, 14; ГУ «Институт неотложной и восстановительной хирургии имени В.К.Гусака НАМН Украины»: 83000, Украина, Донецк, Ленинский проспект, 47УкраинаM.Gor'kiy Donetsk National Medical University: 14; Il'icha av., Donetsk, 83005, Ukraine;UkraineДонецкий национальный медицинский университет имени М.Горького: 83005, Украина, Донецк, пр. Ильича, 14УкраинаM.Gor'kiy Donetsk National Medical University: 14; Il'icha av., Donetsk, 83005, Ukraine;Ukraine201620122016265610617Copyright © Ватутин Н.Т., Смирнова А.С., Борт Д.В., Тарадин Г.Г., 20162016Ватутин Н.Т., Смирнова А.С., Борт Д.В., Тарадин Г.Г.Vatutin N.T., Smirnova A.S., Bort D.V., Taradin G.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/770

В настоящее время хроническая обструктивная болезнь легких рассматривается как системное заболевание с множественными внелегочными проявлениями, которые в ряде случаев и определяют прогноз. При этом сердечно-сосудистые осложнения относятся к основным системным проявлениям заболевания. Появление кардиореспираторной коморбидности, сопровождающейся синдромом взаимного отягощения, формирует определенные особенности клинической картины ввиду общности некоторых звеньев патогенеза, которые включают развитие системного воспалительного ответа, оксидативного стресса и эндотелиальной дисфункции. В обзоре представлены основные патогенетические механизмы, характерные для данной коморбидной патологии.

Chronic obstructive pulmonary disease (COPD) is currently considered as a systemic disease with multiple extrapulmonary manifestations which can negatively affect the prognosis. Cardiovascular abnormalities are main systemic manifestations of COPD. Cardiovascular diseases and COPD have common pathogenic features that include the systemic inflammatory response, oxidative stress and endothelial dysfunction. Main pathogenic mechanisms of this comorbidity were discussed in this review.

хроническая обструктивная болезнь легкихсердечно-сосудистые заболеванияпатогенезchronic obstructive pulmonary diseasecardiovascular diseasepathogenesisReferencesMurray C.J., Lopez A.D. Measuring the global burden of disease. N. Engl. J. Med. 2013; 369: 448–457.Murray C.J., Lopez A.D. Measuring the global burden of disease. N. Engl. J. Med. 2013; 369: 448–457.Agusti A., Calverley P.M., Celli B. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.Agusti A., Calverley P.M., Celli B. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Global Initiative for Chronic Obstructive lung Disease (GOLD). The updated 2015 report is available at www.goldcopd.com).Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Global Initiative for Chronic Obstructive lung Disease (GOLD). The updated 2015 report is available at www.goldcopd.com).Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54.Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Federal clinical guidelines on diagnosis and management of chronic obstructive pulmonary disease. Pul'monologiya. 2014; 3: 15–54 (in Russian).Pan J., Xu L., Cai S.X. et al. The association of pulmonary function with carotid atherosclerosis in older Chinese: Guangzhou Biobank Cohort Study-CVD Subcohort. Atherosclerosis. 2015; 243 (2): 469–476.Pan J., Xu L., Cai S.X. et al. The association of pulmonary function with carotid atherosclerosis in older Chinese: Guangzhou Biobank Cohort Study-CVD Subcohort. Atherosclerosis. 2015; 243 (2): 469–476.Крюков Н.Н., Шанина И.Ю., Протасов А.Д. Результаты функциональных тестов у больных с ИБС в сочетании с ХОБЛ. Фундаментальные исследования. 2011; 2: 83–88.Kryukov N.N., Shanina I.Yu., Protasov A.D. Results of functional tests in patients with comorbidity of coronary heart disease and chronic obstructive pulmonary disease. Fundamental'nye issledovaniya. 2011; 2: 83–88 (in Russian).Sin D.D., Man S.F.P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2: 8–11.Sin D.D., Man S.F.P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2: 8–11.Беловол А.Н., Князькова И.И., Цыганков А.И. и др. Оптимизация лечения больных хронической сердечной недостаточностью в сочетании с хроническим обструктивным заболеванием легких. Практична ангіологія. 2015; 3 (70): 57–62.Belovol A.N., Knyaz'kova I.I., Tsygankov A.I. et al. Improvement in therapy of patients with chronic heart failure and chronic obstructive pulmonary disease. Praktichna angіologіya. 2015; 3 (70): 57–62 (in Russian).Кубажи Халил. Особенности течения и прогноза у больных хронической обструктивной болезнью лёгких в сочетании с ишемической болезнью сердца и артериальной гипертензией: Дисс. канд. мед. наук. Рязань; 2013.Kubazhi Khalil. Disease course and prognosis in patients with comorbidity of chronic obstructive pulmonary disease, coronary heart disease and hypertension: Diss. Ryazan'; 2013 (in Russian).Rodriguez-Miguelez P., Seigler N., Bass L. et al. Assessments of endothelial function and arterial stiffness are reproducible in patients with COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1977–1986.Rodriguez-Miguelez P., Seigler N., Bass L. et al. Assessments of endothelial function and arterial stiffness are reproducible in patients with COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1977–1986.Campo G., Pavasini R., Malagù M. et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc. Drugs Ther. 2015; 29 (2): 147–157.Campo G., Pavasini R., Malagù M. et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc. Drugs Ther. 2015; 29 (2): 147–157.Куценко М.А., Чучалин А.Г. Парадигма коморбидности: синтропия ХОБЛ и ИБС. Русский медицинский журнал. 2014; 5: 389–393.Kutsenko M.A., Chuchalin A.G. A paradigm of comorbidity of chronic obstructive pulmonary disease and coronary heart disease. Russkiy meditsinskiy zhurnal. 2014; 5: 389–393 (in Russian).Ярмыш Н.В., Грозная Л.Н. Эндотелиальная дисфункция и ее регуляторные факторы. Вісник проблем біології і медицини. 2014; 2 (111): 37–43.Yarmysh N.V., Groznaya L.N. Endothelial dysfunction and regulatory factors. Vіsnik problem bіologії і meditsini. 2014; 2 (111): 37–43 (in Russian).Fabbri L.M., Rabe K.F., Ukena C. et al. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007; 370: 797–799.Fabbri L.M., Rabe K.F., Ukena C. et al. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007; 370: 797–799.Мамаева М.Г., Демко И.В., Вериго Я.И. и др. Маркеры системного воспаления и эндотелиальной дисфункции у больных хронической обструктивной болезнью легких. Сибирское медицинское обозрение. 2014; 1 (85): 12–19.Mamaeva M.G., Demko I.V., Verigo Ya.I. et al. Markers of systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease. Sibirskoe meditsinskoe obozrenie. 2014; 1 (85): 12–19 (in Russian).Pepene C.E. Soluble platelet/endothelial cell adhesion molecule (sPECAM)-1 is increased in polycystic ovary syndrome and related to endothelial dysfunction. Gynecol. Endocrinol. 2012; 28 (5): 370–374.Pepene C.E. Soluble platelet/endothelial cell adhesion molecule (sPECAM)-1 is increased in polycystic ovary syndrome and related to endothelial dysfunction. Gynecol. Endocrinol. 2012; 28 (5): 370–374.Hou H.F., Yuan N., Guo Q. et al. Citreoviridin enhances atherogenesis in hypercholesterolemic ApoE-deficient mice via upregulating inflammation and endothelial dysfunction. PLoS One. 2015; 10 (5): e0125956.Hou H.F., Yuan N., Guo Q. et al. Citreoviridin enhances atherogenesis in hypercholesterolemic ApoE-deficient mice via upregulating inflammation and endothelial dysfunction. PLoS One. 2015; 10 (5): e0125956.Bakakos P., Patentalakis G., Papi A. Vascular biomarkers in asthma and COPD. Curr. Top. Med. Chem. 2016; 16 (14): 1599–1609.Bakakos P., Patentalakis G., Papi A. Vascular biomarkers in asthma and COPD. Curr. Top. Med. Chem. 2016; 16 (14): 1599–1609.Поплавская Э.Э., Лис М.А. Состояние функции эндотелия и активность фагоцитоза при хронической обструктивной болезни легких и ишемической болезни сердца. Журнал Гродненского государственного медицинского университета. 2010; 1 (29): 29–31.Poplavskaya E.E., Lis M.A. Endothelial function and phagocytosis activity in comorbidity of chronic obstructive pulmonary disease and coronary heart disease. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta. 2010; 1 (29): 29–31 (in Russian).Зарубина Е.Г., Мишина Е.А., Осадчук М.А. Роль эндотелиальной дисфункции в патогенезе сочетанных сердечно-легочных заболеваний. Клиническая медицина. 2006; 5: 31–34.Zarubina E.G., Mishina E.A., Osadchuk M.A. A role of endothelial dysfunction in pathogenesis of heart and respiratory disease comorbidity. Klinicheskaya meditsina. 2006; 5: 31–34 (in Russian).Takahashi T., Kubo H. The role of microparticles in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 303–314.Takahashi T., Kubo H. The role of microparticles in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 303–314.Tanaseanu C., Tudor S., Tamsulea I. et al. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus. Eur. J. Med. Res. 2007; 12 (4): 145–151.Tanaseanu C., Tudor S., Tamsulea I. et al. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus. Eur. J. Med. Res. 2007; 12 (4): 145–151.Boeck L., Mandal J., Costa L. et al. Longitudinal measurement of serum vascular endothelial growth factor in patients with chronic obstructive pulmonary disease. Respiration. 2015; 90 (2): 97–104.Boeck L., Mandal J., Costa L. et al. Longitudinal measurement of serum vascular endothelial growth factor in patients with chronic obstructive pulmonary disease. Respiration. 2015; 90 (2): 97–104.Feng E.Z., Yang S.Y., Huang N.X. et al. Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014; 30 (6): 532–537.Feng E.Z., Yang S.Y., Huang N.X. et al. Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014; 30 (6): 532–537.Akhmineeva A.Kh. Biochemical markers of endothelial dysfunction in chronic obstructive pulmonary disease concurrent with hypertensive disease or coronary heart disease. [Article in Russian]. Ter. Arkh. 2014; 86 (3): 20–23.Akhmineeva A.Kh. Biochemical markers of endothelial dysfunction in chronic obstructive pulmonary disease concurrent with hypertensive disease or coronary heart disease. [Article in Russian]. Ter. Arkh. 2014; 86 (3): 20–23.Прибылов С.А. Легочная гипертензия, эндотелиальная дисфункция и их коррекция лизиноприлом у больных с сердечной недостаточностью при сочетании ишемической болезни сердца и хронической обструктивной болезни легких. Кардиология. 2006; 46 (9): 36–40.Pribylov S.A. Pulmonary hypertension, endothelial dysfunction and their correction with Lisinopril in patients with heart failure due to coronary heart disease and chronic obstructive pulmonary disease comorbidity. Kardiologiya. 2006; 46 (9): 36–40 (in Russian).Janssen W.J., Yunt Z.X., Muldrow A. et al. Circulating hematopoietic progenitor cells are decreased in COPD. COPD. 2014; 11 (3): 277–289.Janssen W.J., Yunt Z.X., Muldrow A. et al. Circulating hematopoietic progenitor cells are decreased in COPD. COPD. 2014; 11 (3): 277–289.Pizarro S., García-Lucio J., Peinado V.I. et al. Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary disease. PLoS One. 2014; 9 (8): e106163.Pizarro S., García-Lucio J., Peinado V.I. et al. Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary disease. PLoS One. 2014; 9 (8): e106163.Liu P., Zhang H., Liu J. et al. Changes of number and function of late endothelial progenitor cells in peripheral blood of COPD patients combined with pulmonary hypertension. Thorac. Cardiovasc. Surg. 2014 Sep 16. Epub ahead of print.Liu P., Zhang H., Liu J. et al. Changes of number and function of late endothelial progenitor cells in peripheral blood of COPD patients combined with pulmonary hypertension. Thorac. Cardiovasc. Surg. 2014 Sep 16. Epub ahead of print.Paschalaki K.E., Starke R.D., Hu Y. et al. Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem. Cells. 2013; 31 (12): 2813–2826.Paschalaki K.E., Starke R.D., Hu Y. et al. Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem. Cells. 2013; 31 (12): 2813–2826.Yoshii A., Iizuka K., Dobashi K. et al. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am. J. Respir. Cell Mol. Biol. 1999; 20 (6): 1190–1200.Yoshii A., Iizuka K., Dobashi K. et al. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am. J. Respir. Cell Mol. Biol. 1999; 20 (6): 1190–1200.Fukumoto Y., Matoba T., Ito A. et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005; 91 (3): 391–392.Fukumoto Y., Matoba T., Ito A. et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005; 91 (3): 391–392.Steioff K., Rütten H., Busch A.E. et al. Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice. Eur. J. Pharmacol. 2005; 512 (2–3): 247–249.Steioff K., Rütten H., Busch A.E. et al. Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice. Eur. J. Pharmacol. 2005; 512 (2–3): 247–249.Bei Y., Duong-Quy S., Hua-Huy T. et al. Activation of RhoA/Rho-kinase pathway accounts for pulmonary endothelial dysfunction in patients withchronic obstructive pulmonary disease. Physiol. Rep. 2013; 1 (5): e00105.Bei Y., Duong-Quy S., Hua-Huy T. et al. Activation of RhoA/Rho-kinase pathway accounts for pulmonary endothelial dysfunction in patients withchronic obstructive pulmonary disease. Physiol. Rep. 2013; 1 (5): e00105.Song D., Fang G., Greenberg H., Liu S.F. Chronic intermittent hypoxia exposure-induced atherosclerosis: a brief review. Immunol. Res. 2015; 63 (1–3): 121–130.Song D., Fang G., Greenberg H., Liu S.F. Chronic intermittent hypoxia exposure-induced atherosclerosis: a brief review. Immunol. Res. 2015; 63 (1–3): 121–130.Provotorov V.M., Budnevskiĭ A.V., Semenkova G.G., Shishkina E.S. Proinflammatory cytokines in combination of coronary heart disease and chronic obstructive pulmonary disease. Klin. Med. (Mosk.). 2015; 93 (2): 5–9.Provotorov V.M., Budnevskiĭ A.V., Semenkova G.G., Shishkina E.S. Proinflammatory cytokines in combination of coronary heart disease and chronic obstructive pulmonary disease. Klin. Med. (Mosk.). 2015; 93 (2): 5–9.Карпова А.А., Рейдер Т.Н. Особенности поражения коронарного русла у пациентов с мультифокальным атеросклерозом в сочетании с хронической обструктивной болезнью легких. Фундаментальные исследования. 2014; 4: 286–290.Karpova A.A., Reyder T.N. Coronary injury in patients with multi-focal atherosclerosis and chronic obstructive pulmonary disease. Fundamental'nye issledovaniya. 2014; 4: 286–290 (in Russian).Lin G.M., Liu K., Colangelo L.A. et al. Low-density lipoprotein cholesterol concentrations and sssociation of high-sensitivity C-reactive protein concentrations with incident coronary heart disease in the multi-ethnic study of atherosclerosis. Am. J. Epidemiol. 2016;183 (1): 46–52.Lin G.M., Liu K., Colangelo L.A. et al. Low-density lipoprotein cholesterol concentrations and sssociation of high-sensitivity C-reactive protein concentrations with incident coronary heart disease in the multi-ethnic study of atherosclerosis. Am. J. Epidemiol. 2016;183 (1): 46–52.Stamler J., Neaton J.D., Cohen J.D. et al. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J. Am. Heart Assoc. 2012; 1 (5): e003640.Stamler J., Neaton J.D., Cohen J.D. et al. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J. Am. Heart Assoc. 2012; 1 (5): e003640.Nilsson M., Trehn G., Asplund K. Use of complementary and alternative medicine remedies in Sweden. A population-based longitudinal study within the northern Sweden MONICA Project. Multinational Monitoring of Trends and Determinants of Cardiovascular Disease. J. Intern. Med. 2001; 250 (3): 225–233.Nilsson M., Trehn G., Asplund K. Use of complementary and alternative medicine remedies in Sweden. A population-based longitudinal study within the northern Sweden MONICA Project. Multinational Monitoring of Trends and Determinants of Cardiovascular Disease. J. Intern. Med. 2001; 250 (3): 225–233.Dursunoglu N., Dursunoglu D., Yıldız A.İ. et al. Severity of coronary atherosclerosis in patients with COPD. Clin. Respir. J. 2015. doi: 10.1111/crj.12412. [Epub ahead of print].Dursunoglu N., Dursunoglu D., Yıldız A.İ. et al. Severity of coronary atherosclerosis in patients with COPD. Clin. Respir. J. 2015. doi: 10.1111/crj.12412. [Epub ahead of print].Верткин А.Л., Скотников А.С., Губжокова О.М. Коморбидность при хронической обструктивной болезни легких: роль хронического системного воспаления и клинико-фармакологические ниши рофлумиласта. Лечащий врач. 2013; 11: 85–88.Vertkin A.L., Skotnikov A.S., Gubzhokova O.M. Comorbidity in patients with chronic obstructive pulmonary disease: a role of systemic inflammation and clinical and pharmacological role of roflumilast. Lechashchiy vrach. 2013; 11: 85–88 (in Russian).Акрамова Э.Г., Стручков П.В. Распространенность каротидного атеросклероза у больных ХОБЛ. Пульмонология. 2013; 3: 45–48.Akramova E.G., Struchkov P.V. Severity of carotid atherosclerosis in patients with chronic obstructive pulmonary disease. Pul'monologiya. 2013; 3: 45–48 (in Russian).Провоторов В.М., Будневский А.В., Семенкова Г.Г., Шишкина Е.С. Провоспалительные цитокины при сочетании ишемической болезни сердца и хронической обструктивной болезни легких. Клиническая медицина. 2015; 93 (2): 5–9.Provotorov V.M., Budnevskiy A.V., Semenkova G.G., Shishkina E.S. Proinflammatory cytokines in comorbidity of coronary heart disease and chronic obstructive pulmonary disease. Klinicheskaya meditsina. 2015; 93 (2): 5–9 (in Russian).Полунина О.С., Михайлова И.А, Кудряшёва И.А. Состояние системы гемостаза у больных хронической обструктивной болезнью легких у пожилых. Фундаментальные исследования. 2005; 2: 32–33.Polunina O.S., Mikhaylova I.A, Kudryasheva I.A. Hemostasis in elderly patients with chronic obstructive pulmonary disease. Fundamental'nye issledovaniya. 2005; 2: 32–33 (in Russian).Киняйкин М.Ф., Суханова Г.И., Удовиченко И.А. и др. Роль гипоксемии в формировании миокардиальных повреждений и нарушений гемостаза у больных хронической обструктивной болезнью легких. Бюллетень физиологии и патологии дыхания. 2011; 41: 8–12.Kinyaykin M.F., Sukhanova G.I., Udovichenko I.A., et al. A role of hypoxemia in development of myocardial injury and hemostasis abnormalities in patients with chronic obstructive pulmonary disease. Byulleten' fiziologii i patologii dykhaniya. 2011; 41: 8–12 (in Russian).Biljak V.R., Pancirov D., Cepelak I. et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011; 22 (6): 466–470.Biljak V.R., Pancirov D., Cepelak I. et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011; 22 (6): 466–470.Костин В.И., Простакишина Ю.М., Шангина О.А., Солодилова Т.П. Агрегатное состояние крови у пожилых пациентов с ХОБЛ, страдающих депрессивными расстройствами. Клиническая геронтология. 2012; 11: 21–24.Kostin V.I., Prostakishina Yu.M., Shangina O.A., Solodilova T.P. Blood aggregation in elderly patients with COPD and depressive disorders. Klinicheskaya gerontologiya. 2012; 11: 21–24 (in Russian).Martin-Rodriguez E., Guillen-Grima F., Martí A, Brugos-Larumbe A. Comorbidity associated with obesity in a large population: The APNA study. Obes. Res. Clin. Pract. 2015; 9 (5): 435–447.Martin-Rodriguez E., Guillen-Grima F., Martí A, Brugos-Larumbe A. Comorbidity associated with obesity in a large population: The APNA study. Obes. Res. Clin. Pract. 2015; 9 (5): 435–447.Liu Y., Pleasants R.A., Croft J.B., Lugogo N. et al. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir. Med. 2015; 109 (7): 851–859.Liu Y., Pleasants R.A., Croft J.B., Lugogo N. et al. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir. Med. 2015; 109 (7): 851–859.Laurikka A., Vuolteenaho K., Toikkanen V., Rinne T. Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgery. Eur. J. Cardiothorac. Surg. 2014; 46 (4): 729–736.Laurikka A., Vuolteenaho K., Toikkanen V., Rinne T. Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgery. Eur. J. Cardiothorac. Surg. 2014; 46 (4): 729–736.Lis I., Pilarski Ł., Bogdański P. Omentin – a newly-discovered adipocytokine in insulin resistance pathogenesis. Pol. Merkur. Lekarski. 2015; 39 (229): 56–60.Lis I., Pilarski Ł., Bogdański P. Omentin – a newly-discovered adipocytokine in insulin resistance pathogenesis. Pol. Merkur. Lekarski. 2015; 39 (229): 56–60.Nikseresht M., Sadeghifard N., Agha-Alinejad H., Ebrahim K. Inflammatory markers and adipocytokine responses to exercise training and detraining in men who are obese. J. Strength. Cond. Res. 2014; 28 (12): 3399–3410.Nikseresht M., Sadeghifard N., Agha-Alinejad H., Ebrahim K. Inflammatory markers and adipocytokine responses to exercise training and detraining in men who are obese. J. Strength. Cond. Res. 2014; 28 (12): 3399–3410.

The authors declare that there are no conflicts of interest present.